Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer

Ziwei Yu, Paul M. Weinberger, Clarence Sasaki, Brian L. Egleston, William F. Speier IV, Bruce Haffty, Diane Kowalski, Robert Camp, David Rimm, Eleftherios Vairaktaris, Barbara Burtness and Amanda Psyrri
Ziwei Yu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Weinberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clarence Sasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian L. Egleston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William F. Speier IV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Haffty
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Kowalski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Camp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Rimm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleftherios Vairaktaris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Burtness
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Psyrri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-06-0121 Published March 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Corrections - May 16, 2007

Abstract

Background: Several lines of laboratory evidence support a role of persistent activation of Akt pathway in oropharyngeal squamous cell carcinoma (OSCC) progression. Loss of phosphatase PTEN is one of the proposed mechanisms of Akt activation. We sought to determine the prognostic significance of Akt activation in a cohort of patients with OSCC as well as the association between phosphorylated (activated) Akt and PTEN levels.

Methods: Using a novel system of in situ quantitative protein expression analysis (AQUA), we studied the protein expression levels of phosphorylated Akt (p-Akt) and PTEN on a tissue microarray. The array included 79 OSCCs with a mean follow-up of 36 months.

Results: Patients with tumors expressing low tumor p-Akt levels had lower 5-year local recurrence rates (5% versus 38%). Additionally, these patients had improved 5-year overall survival rates (45% versus 27%). This survival effect was likely due to disease recurrence, as there was no difference in death without recurrence between low- and high-expressing groups. In adjusted analysis, tumor p-Akt expression was a strong predictor of local recurrence. A significant inverse relationship was found between nuclear p-Akt and nuclear PTEN: Tumors with high nuclear p-Akt had low nuclear PTEN and vice versa.

Conclusions: Akt activation in OSCC is associated with adverse patient outcome, indicating that Akt is a promising molecular target in OSCC. PTEN loss may be one of the mechanisms of Akt activation in OSCC. (Cancer Epidemiol Biomarkers Prev 2007;16(3):553–8)

  • Akt
  • Head and neck/oral cancers
  • Risk assessment
  • Signal transduction pathways

Introduction

The prognosis of patients presenting with locally advanced head and neck squamous cell cancer (HNSCC) is still poor, with 5-year actuarial survival rates between 30% and 40% in most studies, despite decades of intensive clinical investigations (1). These poor survival rates combined with the severe functional impairment associated with surgery and radiation underscore the need to develop novel therapeutic strategies in the management of patients with advanced HNSCC. Recently, research efforts have focused on developing molecular targeted therapies or searching for molecular markers that are prognostic or predictive for treatment outcome. The advances in molecular biology with the availability of genomic and proteomic approaches have opened new research directions. Receptor tyrosine kinases have emerged as promising targets for cancer therapy (2-8).

The serine/threonine protein kinase Akt, a downstream target of phosphatidylinositol 3-kinase (PI3K), has been shown to be intimately involved in various cellular processes linked to tumorigenesis, including cell cycle progression, cell survival, cell motility, angiogenesis, as well as regulation of the mammalian target of rapamycin signaling pathway (9). PI3K/Akt pathway is activated by signaling inputs transmitted to the cytoplasm after growth factor ligand binding to receptor tyrosine kinases spanning the plasma membrane, such as epidermal growth factor receptor (EGFR). Specifically, ligand binding to receptors induces activation of the PI3K holoenzyme, leading to its recruitment to the plasma membrane and the formation of phosphoinositol triphosphate. Phosphoinositol triphosphate subsequently activates phosphoinositide-dependent kinase 1, leading to phosphorylation and activation of Akt. PTEN protein, the product of PTEN tumor-suppressor gene, is a lipid phosphatase that, by removing phosphate groups from phosphoinositide signaling molecules, limits the activity of PI3K pathway.

Although persistent activation of Akt pathway in HNSCC has been reported (10), the studies examining the prognostic significance of Akt activation in this tumor type are limited by small sample size and the use of conventional immunohistochemistry for evaluation of p-Akt expression (11, 12).

AQUA is a fully quantitative in situ proteomic method of analysis for tissue microarrays that allows calculation of expression ratios (13). This method allows measurements of protein expression within subcellular compartments that results in a number directly proportional to the number of molecules expressed per unit area (the concentration). This novel technology uses molecular methods to define subcellular compartments. It then quantifies the amount of protein expressed within the compartment by colocalization. Therefore, this technology permits preservation of tissue morphology while quantifying protein expression in paraffin-embedded tissue. In this study, we sought to evaluate the prognostic role of Akt activation by studying the levels of phosphorylated (activated) Akt (Ser473) expression using a cohort oropharyngeal squamous cell cancer (OSCC) tissue microarray and associating expression with clinical and pathologic data. We also sought to examine the correlation between PTEN and p-Akt levels. Our results indicate that increased levels of p-Akt represent an independent adverse prognostic indicator in HNSCC and that PTEN loss is a likely mechanism of Akt activation.

Materials and Methods

Tissue Microarray Construction

Following Yale institutional review board approval, a cohort of patients with OSCC was assembled. Inclusion criteria were histologically confirmed primary squamous cell carcinoma of the oropharynx treated at Yale-New Haven hospital between 1980 and 1999, and therapy with either external beam radiotherapy or gross total surgical resection and postoperative radiotherapy. Exclusion criteria included presentation with metastatic or recurrent disease, non-oropharyngeal site, and failure to receive a full course of radiation therapy. A tissue microarray was constructed as previously described (14), including 79 cases that met inclusion criteria and had complete p-Akt expression data. We excluded from the analysis 15 cases that had missing p-Akt expression information. Tissue cores were obtained from paraffin-embedded, formalin-fixed tissue blocks in the Yale University Department of Pathology archives. Slides from all blocks were reviewed by a pathologist to select representative areas of invasive tumor to be cored. The cores were placed in the recipient microarray block using a Tissue Microarrayer (Beecher Instrument, Silver Spring, MD). All tumors were represented with 2-fold redundancy. Previous studies have shown that the use of tissue microarrays containing one to two histospots provides a sufficiently representative sample for analysis by immunohistochemistry. Addition of a duplicate histospot, although not necessary, provides marginally improved reliability (15). Cores from HPV16-positive SiHa cell lines fixed in formalin and embedded in paraffin were selected for positive controls and included in the array. Additionally, 10 histologically confirmed normal squamous epithelium samples from formalin-fixed and paraffin-embedded skin were included for comparison of p-Akt expression in normal tissue. The tissue microarray was then cut to yield 5-μm sections and placed on glass slides using an adhesive tape transfer system (Instrumedics, Inc., Hackensack, NJ) with UV cross-linking.

Quantitative Immunohistochemistry

Tissue microarray slides were deparaffinized and stained as previously described. In brief, slides were deparrafinized with xylene followed by ethanol. Following rehydration in distilled water, antigen retrieval was accomplished by pressure cooking in 0.1 mol/L citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked by incubating in 0.3% hydrogen peroxide in methanol for 30 min. Nonspecific antibody binding was then blocked with 0.3% bovine serum albumin for 30 min at room temperature. Following these steps, slides were incubated with primary antibody to p-Akt (Ser473), obtained from Cell Signaling Technology (Beverly, MA), at 4°C overnight. The antibody to p-Akt was used at 1:300 dilution. This antibody has been extensively validated in previous studies using immunohistochemistry and Western blot analysis of normal and neoplastic tissue and tumor cell lines (10, 16). Primary antibody to PTEN (Cascade BioScience, clone 6H2.1) was used at 1: 50 dilution in 0.3% bovine serum albumin/TBS. This antibody has been validated in previous studies using immunohistochemistry and Western blot analysis of neoplastic tissue (17-19). Subsequently, slides were incubated with goat anti-mouse secondary antibody conjugated to a horseradish peroxidase–decorated dextran polymer backbone (Envision, DAKO Corp., Carpinteria, CA) for 1 h at room temperature. Tumor cells were identified by use of anticytokeratin antibody cocktail (rabbit anti-pancytokeratin antibody z0622; DAKO) with subsequent goat anti-rabbit antibody conjugated to Alexa 546 fluourophore (A11035, Molecular Probes, Eugene, OR). We added 4′,6-diamidino-2-phenylindole to visualize nuclei. Target (p-Akt, PTEN) molecules were visualized with a fluorescent chromogen (Cy-5-tyramide, Perkin-Elmer Corp., Wellesley, MA). Cy-5 (red) was used because its emission peak is well outside the green-orange spectrum of tissue autofluorescence. Slides were mounted with a polyvinyl alcohol–containing aqueous mounting medium with antifade reagent (n-propyl gallate, Acros Organics, Geel, Belgium).

Automated Image Acquisition and Analysis

Automated image acquisition and analysis using AQUA has been described previously (20). In brief, monochromatic, high-resolution (1,024 × 1,024 pixel; 0.5 μm) images were obtained of each histospot. We distinguished areas of tumor from stromal elements by creating a mask from the cytokeratin signal. 4′,6-Diamidino-2-phenylindole signal was used to identify nuclei, and the cytokeratin signal was used to define cytoplasm. Overlapping pixels (to a 99% confidence interval) were excluded from both compartments. The signal (AQUA score) was scored on a normalized scale of 1 to 255 expressed as pixel intensity divided by the target area. AQUA scores for each subcellular compartment (nuclear and cytoplasmic p-Akt) as well as the tumor mask were recorded. AQUA scores for duplicate tissue cores were averaged to obtain a mean AQUA score for each tumor.

Statistical Analysis

Histospots containing <10% tumor, as assessed by mask area (automated), were excluded from further analysis. Based on a left skewed distribution, automated AQUA scores were dichotomized for some analyses. The lowest quartile (“low expressers”) was compared with the rest of the cohort (“all others”). Comparison of prognostic, treatment, and demographic variables between high/low p-Akt expressers was made using Fisher's exact test for categorical variables and confirmed by χ2 tests. Comparison of age between expression groups was made using t tests.

For cumulative incidence analyses, local recurrence was defined as time from day of diagnosis to development of locally recurrent disease. Death without recurrence was defined as the time from day of diagnosis to death without observation of local recurrence. Overall survival was defined as time from day of diagnosis to death from any cause. Analyses of the cumulative incidence of local recurrence and death without recurrence between the dichotomized p-Akt groups were done using the methods of Gray (21). Overall survival between the dichotomized p-Akt groups was assessed by Kaplan-Meier estimation of the survival function. We used Gray's (21) method for hypothesis testing of the null hypothesis of no population-level difference between high and low p-Akt expression groups in the subdistribution hazards generating the cumulative incidence curves. We used a log-rank test to test a similar hypothesis concerning the Kaplan-Meier survival curves.

Univariable (with p-AKT as a continuous measure as the sole covariate) and multivariable analyses of time until local recurrence and death without local recurrence were done using the proportional hazards competing risk method of Fine and Gray (22). Similar analyses for overall survival were done using a Cox proportional hazards regression. Fine and Gray's (22) model is similar to the traditional Cox proportional hazards model, but the model provides estimates of hazard ratios (HR) associated with the subdistribution hazard of the outcome of interest. The subdistribution hazard is defined to account for the fact that those who have a competing outcome event can never have the outcome event of interest. This is different from the Cox model in which those with competing outcome events are censored and such censoring is assumed to provide no further information about the outcome of interest. More details about Fine and Gray's method can be obtained from Resche-Rigon et al. (23). In multivariable regression analyses, we added as covariates p-Akt expression level and all variables listed in Table 1 ; we believed that the variables in Table 1 could be possible confounders of the relationship between p-Akt expression (in and of itself) and local recurrence or survival. We excluded those with missing covariate information from the multivariable analyses. We also excluded from multivariable analyses those with cancers located in other locations of the oropharynx because there were too few cases (four with high p-Akt expression) to reliably estimate a variable associated with this subgroup, and hence adequately adjust for potential confounding. We entered the discrete variables into the multivariable models as categorical variables. We entered age into the models using a restricted cubic spline with one interior knot to allow for a nonlinear relationship between age and recurrence or survival.

View this table:
  • View inline
  • View popup
Table 1.

Demographic, clinical, and pathologic data by p-Akt status

We used the R software package to implement Gray's (21) and Fine and Gray's (22) methods. We used STATA for all other analyses. All statistical tests were two-tailed where applicable.

Results

Clinical and Pathologic Variable Analysis

There were 79 patients with primary oropharyngeal carcinoma in this cohort who met inclusion criteria. Sixty were male, 29 female with age ranging from 41 to 79 years (median 61 years). Nine patients were tumor-node-metastasis (TNM) stage II, 23 stage III, and 47 stage IV. Oropharyngeal subsites included 38 tonsillar fossae, 37 base of the tongue, and 5 other oropharynx. For histologic grade, 5 tumors were well differentiated, 38 were moderately differentiated, 26 were poorly differentiated, and 11 were not recorded. Forty-seven patients were treated by primary radiation therapy alone, and 30 by surgery with postoperative radiation (two patients were not recorded). Twenty-one patients received chemotherapy in addition to their primary treatment modality. These data are summarized in Table 1.

Quantitative Immunohistochemistry for p-Akt Protein Expression

As visualized by fluorescent immunohistochemistry, p-Akt displayed mixed cytoplasmic and nuclear staining (Fig. 1 ). Normalized AQUA scores for p-Akt expression in tumors ranged from 1 to 255. Positive controls (SiHa cell lines) were in the top quartile (data not shown). Histogram analysis of p-AKT expression shows a left-skewed distribution where a number of cases (18%) exhibit p-AKT levels 1 SD below the mean (Fig. 2 ). Table 1 compares characteristics between low and high p-Akt expression groups. There were no statistically significant differences between the two groups.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Fluorescent immunohistochemistry for p-Akt (Ser473). Tumor cells displayed mixed cytoplasmic and nuclear expression of p-Akt.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Histogram of p-AKT expression. There is a left-skewed distribution where a number of cases (18%) exhibit p-AKT levels 1 SD below the mean.

Quantitative Immunohistochemistry (Automated Image Acquisition and Analysis) of PTEN Expression

Seventy-one percent (67 of 79) of tissue spots had sufficient tissue for analysis of PTEN expression by AQUA. PTEN displayed a primarily nuclear expression pattern by immunofluorescence analysis, and normalized AQUA scores were reported on a 1 to 255 scale.

Correlation of p-Akt and PTEN Expression by AQUA

The associations between tumor and nuclear PTEN and p-Akt expression (as determined by AQUA) were analyzed by Spearman correlation. There was no relationship between tumor PTEN and tumor p-Akt expression. For nuclear expression, a significant inverse relationship was found where tumors with high p-Akt in the nucleus had low PTEN in the nucleus and vice versa (Spearman ρ = −0.249, P = 0.045).

Survival Analysis

Univariable Analysis

Tumor p-Akt as determined by AQUA was examined for association with local recurrence, survival without recurrence, and overall survival. To assess the prognostic value of p-Akt expression on a continuous scale, we used the proportional hazards competing risk regression method of Fine and Gray (22). Tumor p-Akt as a continuous variable was a significant predictor for local recurrence (P = 0.01), but not for death without recurrence (see Table 2 ). Tumor p-Akt showed a marginally statistically significant association with overall survival (P = 0.08). The magnitude of these effects was clinically relevant; although the point estimates were small, the range of p-AKT expression in the data set was large (1-242), and hence a sizable difference in p-Akt expression would also be associated with a sizable difference in the relative risk of developing local recurrence or dying.

View this table:
  • View inline
  • View popup
Table 2.

Univariable proportional hazards competing risks and Cox models (n = 79)

Based on the presence of a low-expressing p-Akt group, we did additional univariable analyses comparing incidence and survival curves between low- and high-expressing p-AKT groups (Figs. 3 and 4 ). This analysis showed that cases with low p-AKT expression exhibit a decreased risk of 5-year local recurrence (5.3% versus 38.2%, P = 0.014), and a higher 5-year survival probability (44.9% versus 27.9%, P = 0.05). Table 3 presents 5-year local recurrence and mortality outcomes based on the Gray cumulative incidence and Kaplan-Meier estimates.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Incidence curve comparing local recurrence estimation between low- and high-expressing p-AKT groups. Cases with low p-AKT expression exhibit a decreased risk of local recurrence (5.3% versus 38.2%, P = 0.014).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Kaplan-Meier survival curve comparing overall survival estimation between low- and high-expressing p-AKT groups. Cases with low p-AKT expression exhibit a higher probability of survival (44.9% versus 27.9%, P = 0.05).

View this table:
  • View inline
  • View popup
Table 3.

Local recurrence and mortality outcomes based on the Gray cumulative incidence and Kaplan-Meier estimates

Multivariable Analysis

Using Fine and Gray's method, we did multivariable analyses to assess the independent predictive value of p-Akt tumor expression as a continuous variable for local recurrence and death without recurrence. The following prognostic and potentially confounding variables were also included: sex, age, chemotherapy status, subsite within oropharynx, TNM stage, management (external beam radiotherapy versus primary surgical excision plus external beam radiotherapy), and histologic grade. In these models, p-Akt as a continuous variable was a strong predictor of local recurrence (P = 0.03; see Table 4 ) after controlling for the potential confounding covariates, but not death without local recurrence (P = 0.78; results not shown). Again, because the range of p-Akt was so large, the magnitude of the effect in the regression model presented in Table 4 was substantial. A large increase in p-Akt is associated in the sample with a negative effect on recurrence even after controlling for prognostic and potentially confounding covariates. As a sensitivity analysis to examine whether our assumption of proportional hazards over time held, we also included an interaction between time and p-AKT status in the competing risk regressions to allow for a time-varying HR. The interaction term in the competing risk regressions was not statistically significant, indicating that the data do not provide evidence of a time-varying p-Akt effect. The effect of p-Akt on overall survival in the multivariable Cox model was not statistically significant (P = 0.28; results not shown).

View this table:
  • View inline
  • View popup
Table 4.

Competing risk model of time to local recurrence (n = 66)

Discussion

In this study, we show that increased p-Akt level in OSCC is a strong predictor for poor patient outcome. In multivariable analysis, adjusted for well-recognized prognostic indicators, p-Akt status remained a strong predictor, whereas TNM stage did not. Our data suggest that p-Akt status may be a powerful prognostic marker in OSCC. Further study is needed to determine whether it may also predict benefit from or resistance to therapy or constitute an important therapeutic target.

Two other groups have shown that p-Akt is associated with poor prognosis in oral cancer (11, 24). However, both of these studies used conventional immunohistochemistry to assess p-Akt status. Measurement of protein levels with conventional immunohistochemistry often fails to provide accurate results. Specifically, the pathologist tends to group things as positive or negative, whereas the automated device yields results in continuous full-scale scores. Two prior studies used two different immunohistochemical cutoffs (15% and 20%) to differentiate between “high” versus “low” expressers. The present study is the only one of its kind that uses a quantitative method of protein analysis to determine the prognostic value of Akt activation in oropharyngeal cancer. This method allows measurements of protein expression within subcellular compartments and generates a numerical result directly proportional to the number of molecules expressed per unit area (25). Thus, we avoid biases introduced from the arbitrary cutoff points used in conventional immunohistochemistry studies while preserving spatial and morphologic information that techniques such as Western blotting lose.

Activation of Akt in tumors is mediated via several mechanisms, including activation of cell membrane receptor tyrosine kinases such as EGFR and loss of phosphatase PTEN with dephosphorylation of phosphoinositol triphosphate. In HNSCC, amplification of the 3q26 chromosomal region has also been reported (26). The gene PIK3CA, encoding the catalytic subunit of PI3K (p110), resides at this area (27). Amplification of PIK3CA leads to Akt activation. Whether the remarkable activation of Akt in OSCC results from a unique event or from multiple unrelated molecular mechanisms converging on PI3K activation is presently unknown. Akt activity was found to increase in parallel with the promotion stages of mouse skin carcinogenesis and remained high during the malignant conversion of papillomas to squamous cell carcinoma (28). In one study, simultaneous abnormalities in Akt and p53 pathways in upper aerodigestive tract tumors were rare, indicating that amplification of PIK3CA and mutation of p53 are mutually exclusive events and either event is able to promote a malignant phenotype (26).

Taken together, these studies suggest that Akt activation is an early event in head and neck carcinogenesis, sufficient to induce malignant conversion independent of p53 tumor-suppressor pathway inactivation. Experiments in our laboratory are under way to determine the association between p-Akt expression and expression of related proteins, such as p53, EGFR, PTEN, and PIK3CA in OSCC.

In addition to providing useful prognostic information, our results have important clinical implications. Akt inhibitors, such as UCN-01, and inhibitors of the p-Akt target mammalian target of rapamycin are currently in clinical development. In addition, constitutively activated Akt has been implicated in resistance to EGFR-targeted therapies and EGFR is an established molecular target in HNSCC. So, the combination of EGFR and Akt inhibitors may prove to be a promising therapeutic strategy for OSCC. In the future, p-Akt AQUA score may be useful in predicting response to Akt-targeted therapies.

Footnotes

  • Grant support: Yale University School of Medicine Institutional startup funds (A. Psyrri), the Doris Duke Charitable Foundation (P.M. Weinberger), and the Virginia Alden Wright Fund (C. Sasaki).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 12, 2007.
    • Received February 20, 2006.
    • Revision received November 28, 2006.

References

  1. ↵
    Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002;9:387–99.
    OpenUrlPubMed
  2. ↵
    Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462–9.
    OpenUrlAbstract/FREE Full Text
  3. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312–9.
    OpenUrlAbstract/FREE Full Text
  4. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387–93.
    OpenUrlCrossRefPubMed
  5. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345–55.
    OpenUrlAbstract/FREE Full Text
  6. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004;41:267–73.
    OpenUrlCrossRefPubMed
  7. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274–83.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Ellis AG, Doherty MM, Walker F, et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol 2006;10:1422–34.
  9. ↵
    Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954–63.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10:4029–37.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Massarelli E, Liu DD, Lee JJ, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005;104:2430–6.
    OpenUrlCrossRefPubMed
  12. ↵
    Zhang PL, Pellitteri PK, Law A, et al. Overexpression of phosphorylated nuclear factor-κ B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005;18:924–32.
    OpenUrlCrossRefPubMed
  13. ↵
    Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323–7.
    OpenUrlCrossRefPubMed
  14. ↵
    Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004;10:5684–91.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24–31.
    OpenUrlPubMed
  16. ↵
    Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232–6.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-1 in MCF-7 cells. Cancer Res 2003;63:282–6.
    OpenUrlAbstract/FREE Full Text
  18. Schondorf T, Hoopmann M, Eversheim B, et al. Expression of the tumor suppressor gene PTEN is not altered in the progression of ovarian carcinomas and does not correlate with p27Kip1 expression. Oncol Rep 2003;10:1717–22.
    OpenUrlPubMed
  19. ↵
    Dupont J, Renou JP, Shani M, Hennighausen L, LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest 2002;110:815–25.
    OpenUrlCrossRefPubMed
  20. ↵
    Yu Z, Weinberger PM, Provost E, et al. β-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 2005;11:2471–7.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Gray R. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–54.
  22. ↵
    Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
  23. ↵
    Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care 2006;10:R5.
    OpenUrlCrossRefPubMed
  24. ↵
    Lim J, Kim JH, Paeng JY, et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005;58:1199–205.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808–15.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984–93.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107–23.
    OpenUrlPubMed
  28. ↵
    Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002;21:53–64.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 16 (3)
March 2007
Volume 16, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Ziwei Yu, Paul M. Weinberger, Clarence Sasaki, Brian L. Egleston, William F. Speier IV, Bruce Haffty, Diane Kowalski, Robert Camp, David Rimm, Eleftherios Vairaktaris, Barbara Burtness and Amanda Psyrri
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 553-558; DOI: 10.1158/1055-9965.EPI-06-0121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Ziwei Yu, Paul M. Weinberger, Clarence Sasaki, Brian L. Egleston, William F. Speier IV, Bruce Haffty, Diane Kowalski, Robert Camp, David Rimm, Eleftherios Vairaktaris, Barbara Burtness and Amanda Psyrri
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 553-558; DOI: 10.1158/1055-9965.EPI-06-0121
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement